The Experts below are selected from a list of 7863 Experts worldwide ranked by ideXlab platform

Shaozhen Zhao - One of the best experts on this subject based on the ideXlab platform.

  • gene based therapeutic tools in the treatment of Cornea Disease
    Current Gene Therapy, 2019
    Co-Authors: Shaozhen Zhao
    Abstract:

    Background As one of the main blinding ocular Diseases, Corneal blindness resulted from neovascularization that disrupts the angiogenic privilege of Corneal avascularity. Following neovascularization, inflammatory cells are infiltrating into Cornea to strengthen Corneal injury. How to maintain Corneal angiogenic privilege to treat Corneal Disease has been investigated for decades. Methodology Local administration of viral and non-viral-mediated anti-angiogenic factors reduces angiogenic protein expression in situ with limited or free of off-target effects upon gene delivery. Recently, Mesenchymal Stem Cells (MSCs) have been studied to treat Corneal Diseases. Once MSCs are manipulated to express certain genes of interest, they could achieve superior therapeutic efficacy after transplantation. Discussion In the text, we first introduce the pathological development of Corneal Disease in the aspects of neovascularization and inflammation. We summarize how MSCs become an ideal candidate in cell therapy for treating injured Cornea, focusing on cell biology, property and features. We provide an updated review of gene-based therapies in animals and preclinical studies in the aspects of controlling target gene expression, safety and efficacy. Gene transfer vectors are potent to induce candidate protein expression. Delivered by vectors, MSCs are equipped with certain characters by expressing a protein of interest, which facilitates better for MSC-mediated therapeutic intervention for the treatment of Corneal Disease. Conclusion As the core of this review, we discuss how MSCs could be engineered to be vector system to achieve enhanced therapeutic efficiency after injection.

Eric Shiuey - One of the best experts on this subject based on the ideXlab platform.

  • a foldable nonpenetrating keratoprosthesis medium to long term clinical results in patients with Corneal blindness due to noninflammatory anterior Cornea Disease
    Middle East African Journal of Ophthalmology, 2020
    Co-Authors: Jose M Vargas, Eric Shiuey
    Abstract:

    PURPOSE: To report the medium to long-term safety and performance outcomes of the KeraKlear nonpenetrating artificial Cornea (KeraKlear) as the primary procedure in patients with Corneal blindness due to noninflammatory anterior Cornea Disease. METHODS: Fifteen patients with Corneal blindness (preoperative visual acuity [VA] of ≥20/200) due to a non-inflammatory anterior Corneal condition were included in this prospective, single-center study. Preoperative diagnoses included Corneal scars, keratoconus, and Corneal dystrophies. Diseased Corneas were implanted with the KeraKlear (KeraMed Inc., Irvine, California, USA) by a single surgeon (JMV) using a femtosecond laser to create all incisions. Participants were followed up with for as long as 64 months. Uncorrected Snellen VA and postoperative complications were recorded. RESULTS: The average age at the time of surgery was 49.6 years old and 67% of patients were female. The patients experienced an average improvement in uncorrected Snellen VA of 7.6 lines (−1.17 logMAR). Average uncorrected vision at the last visit was 20/100 (0.73 logMAR), and median uncorrected vision at the last visit was 20/70 (0.54 logMAR). One patient experienced extrusion of the KeraKlear due to infection. There were no cases of glaucoma, retroprosthetic membrane, or endophthalmitis, the three most common complications of penetrating keratoprostheses (KPro). CONCLUSIONS: Medium and long-term outcomes of the KeraKlear indicate that this device is a viable alternative to Corneal transplantation as a primary procedure in patients with non-inflammatory causes of Corneal blindness, especially when Corneal tissue is not available.The KeraKlear does not penetrate into the anterior chamber, and therefore, is less susceptible to the most common complications of penetrating KPro including endophthalmitis, glaucoma, and retroprosthetic membrane.The KeraKlear also has a comparable or improved adverse event rate compared to penetrating keratoplasty.

Jose M Vargas - One of the best experts on this subject based on the ideXlab platform.

  • a foldable nonpenetrating keratoprosthesis medium to long term clinical results in patients with Corneal blindness due to noninflammatory anterior Cornea Disease
    Middle East African Journal of Ophthalmology, 2020
    Co-Authors: Jose M Vargas, Eric Shiuey
    Abstract:

    PURPOSE: To report the medium to long-term safety and performance outcomes of the KeraKlear nonpenetrating artificial Cornea (KeraKlear) as the primary procedure in patients with Corneal blindness due to noninflammatory anterior Cornea Disease. METHODS: Fifteen patients with Corneal blindness (preoperative visual acuity [VA] of ≥20/200) due to a non-inflammatory anterior Corneal condition were included in this prospective, single-center study. Preoperative diagnoses included Corneal scars, keratoconus, and Corneal dystrophies. Diseased Corneas were implanted with the KeraKlear (KeraMed Inc., Irvine, California, USA) by a single surgeon (JMV) using a femtosecond laser to create all incisions. Participants were followed up with for as long as 64 months. Uncorrected Snellen VA and postoperative complications were recorded. RESULTS: The average age at the time of surgery was 49.6 years old and 67% of patients were female. The patients experienced an average improvement in uncorrected Snellen VA of 7.6 lines (−1.17 logMAR). Average uncorrected vision at the last visit was 20/100 (0.73 logMAR), and median uncorrected vision at the last visit was 20/70 (0.54 logMAR). One patient experienced extrusion of the KeraKlear due to infection. There were no cases of glaucoma, retroprosthetic membrane, or endophthalmitis, the three most common complications of penetrating keratoprostheses (KPro). CONCLUSIONS: Medium and long-term outcomes of the KeraKlear indicate that this device is a viable alternative to Corneal transplantation as a primary procedure in patients with non-inflammatory causes of Corneal blindness, especially when Corneal tissue is not available.The KeraKlear does not penetrate into the anterior chamber, and therefore, is less susceptible to the most common complications of penetrating KPro including endophthalmitis, glaucoma, and retroprosthetic membrane.The KeraKlear also has a comparable or improved adverse event rate compared to penetrating keratoplasty.

Jorge L Alio - One of the best experts on this subject based on the ideXlab platform.

  • Corneal stroma regeneration new approach for the treatment of Cornea Disease
    Asia-Pacific journal of ophthalmology, 2020
    Co-Authors: Mona El Zarif, Jorge Alio L Del Barrio, Francisco Arnalichmontiel, Maria P De Miguel, Nehman Makdissy, Jorge L Alio
    Abstract:

    Corneal grafting is one of the most common forms of human tissue transplantation. The Corneal stroma is responsible for many characteristics of the Cornea. For these reasons, an important volume of research has been made to replicate the Corneal stroma in the laboratory to find an alternative to classical Corneal transplantation techniques.There is an increasing interest today in cell therapy of the Corneal stroma using induced pluripotent stem cells or mesenchymal stem cells since these cells have shown to be capable of producing new collagen within the host stroma and even to improve its transparency.The first clinical experiment on Corneal stroma regeneration in advanced keratoconus cases has been reported and included. Fourteen patients were randomized and enrolled into 3 experimental groups: (1) patients underwent implantation of autologous adipose-derived adult stem cells alone, (2) patients received decellularized donor Corneal stroma laminas, and (3) patients received implantation of recellularized donor laminas with adipose-derived adult stem cells. Clinical improvement was detected with all cases in their visual, pachymetric, and topographic parameters of the operated Corneas.Other recent studies have used allogenic SMILE implantation lenticule Corneal inlays, showing also an improvement in different visual, topographic, and keratometric parameters.In the present report, we try to summarize the available preclinical and clinical evidence about the emerging topic of Corneal stroma regeneration.

Feng-gang Wang - One of the best experts on this subject based on the ideXlab platform.

  • Observation of deep lamellar keratoplasty for Cornea Disease
    Chinese Journal of Ocular Trauma and Occupational Eye Disease, 2012
    Co-Authors: Xu-pan Chen, Feng-gang Wang
    Abstract:

    Objective To observe the clinicsl efficacy and complications of deep lamellar keratoplasty(DAKL) in patients with Cornea disesse.Mathods Using glycerine cryopreserved Corneal tissues for deep lamellar keratoplasty in 15 cases (15 eyes) and it's efficacy were observed and analyzed.The patients were followed up for 14 ～ 18 months.Results The best corrected visual acuity of all patients was improved postoperatively.0.08 in 1,4 eyes were 0.12～0.25,6 eyes were 0.3～0.5 and ≥0.6 in 4 eyes; 11 eyes of Corneal graft transparent in 1 week,3 graft transparent within 2 weeks,inherent wrinkle of Descement' s Corneal translucent 1 eye;one cases of postoperative recurrent viral keratitis Corneal scar nebula healing.the rest did not have Corneal Disease rejection.Conclusion Deep lamellar keratoplasty for the treatment of the Corneal Disease provides a safe and effective option,with good visual acuity,fewer complications,and the material condition of the donor requirement is low. Key words: Deep lamellar, keratoplasty;  Efficacy;  Complication